inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Cristiana Pires CEO discusses the increasing traction of cellular reprogramming within the investor community in Portuguese newspaper Expresso.

Posted 25 January, 2022